DE69033949D1 - Aus hausstaub isoliertes t-zellreaktives katzenprotein, und dessen verwendungen - Google Patents

Aus hausstaub isoliertes t-zellreaktives katzenprotein, und dessen verwendungen

Info

Publication number
DE69033949D1
DE69033949D1 DE69033949T DE69033949T DE69033949D1 DE 69033949 D1 DE69033949 D1 DE 69033949D1 DE 69033949 T DE69033949 T DE 69033949T DE 69033949 T DE69033949 T DE 69033949T DE 69033949 D1 DE69033949 D1 DE 69033949D1
Authority
DE
Germany
Prior art keywords
trfp
peptide
dust
cell reactive
protein isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69033949T
Other languages
English (en)
Other versions
DE69033949T2 (de
Inventor
L Gefter
D Garman
L Greenstein
Mei-Chang Kuo
L Rogers
W Brauer
Irwin J Griffith
Jay Boston Morgenstern
Julian Bond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Immulogic Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharmaceutical Corp filed Critical Immulogic Pharmaceutical Corp
Publication of DE69033949D1 publication Critical patent/DE69033949D1/de
Application granted granted Critical
Publication of DE69033949T2 publication Critical patent/DE69033949T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
DE69033949T 1989-11-03 1990-11-02 Aus hausstaub isoliertes t-zellreaktives katzenprotein, und dessen verwendungen Expired - Lifetime DE69033949T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43156589A 1989-11-03 1989-11-03
PCT/US1990/006548 WO1991006571A1 (en) 1989-11-03 1990-11-02 A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor

Publications (2)

Publication Number Publication Date
DE69033949D1 true DE69033949D1 (de) 2002-05-23
DE69033949T2 DE69033949T2 (de) 2002-11-14

Family

ID=23712496

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69033949T Expired - Lifetime DE69033949T2 (de) 1989-11-03 1990-11-02 Aus hausstaub isoliertes t-zellreaktives katzenprotein, und dessen verwendungen

Country Status (11)

Country Link
EP (1) EP0500785B1 (de)
JP (1) JP3251012B2 (de)
AT (1) ATE216401T1 (de)
AU (1) AU650249B2 (de)
CA (1) CA2073045C (de)
DE (1) DE69033949T2 (de)
DK (1) DK0500785T3 (de)
ES (1) ES2174822T3 (de)
FI (1) FI921979A (de)
NO (1) NO921697L (de)
WO (1) WO1991006571A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328991A (en) * 1989-11-03 1994-07-12 Immulogic Pharmaceutical Corp. Preparation of alkali-modified cat dander allergen (Fel d I) for immunotherapeutic purposes
US5547669A (en) * 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
US6120769A (en) * 1989-11-03 2000-09-19 Immulogic Pharmaceutical Corporation Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
US6019972A (en) * 1989-11-03 2000-02-01 Immulogic Pharmaceutical Corporation Peptides of human T cell reactive feline protein (TRFP)
DE69233772D1 (de) * 1991-10-16 2009-11-12 Merck Patent Gmbh T-zell epitopen von den wichtigsten allergene von dermatophagoides (hausmilbe)
US7288256B1 (en) 1991-10-16 2007-10-30 Merck Patent Gmbh T cell epitopes of the major allergens from dermatophagoides (house dust mite)
KR100271417B1 (ko) * 1991-10-16 2000-12-01 스타세이 엘. 첸닝 재조합 펩티드
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
US5820862A (en) * 1994-04-14 1998-10-13 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
ATE412175T1 (de) * 1996-03-21 2008-11-15 Circassia Ltd Verwendung von kryptischen peptiden zur induktion von immunologischer toleranz
DE19713001A1 (de) * 1997-03-27 1998-10-01 Merck Patent Gmbh Graminaenpollenallergenmutanten zur spezifischen Immuntherapie, deren Herstellung und Verwendung
US6143496A (en) 1997-04-17 2000-11-07 Cytonix Corporation Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly
JP2002501748A (ja) 1998-01-31 2002-01-22 ユニバーシティ オブ アーカンソー アレルギー反応を減少させるための方法および試薬
US7879977B2 (en) 1998-01-31 2011-02-01 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US8246945B2 (en) 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
EP1272213B1 (de) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbielles wirkstoffabgabesystem
WO2002051430A2 (en) 2000-12-22 2002-07-04 Synovis Limited Methods of modulating toll-related receptor (trr) signaling
BRPI0411127A (pt) 2003-06-10 2006-05-23 Univ Melbourne composição de matéria para modulação de resposta imuno num sujeito a um antìgeno alvo e respectivos método de modulação, processo de produção de células de apresentação de antìgeno e método de tratamento e/ou profilaxia de doença ou condição associada à presença de antìgeno alvo de interesse
JP5021309B2 (ja) 2003-10-16 2012-09-05 ステファン ジョン ラルフ 免疫調節性組成物およびその使用方法
GB0402131D0 (en) 2004-01-30 2004-03-03 Isis Innovation Delivery method
CA2702340C (en) 2006-10-12 2014-12-16 The University Of Queensland Compositions and methods for modulating immune responses
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
PL2083856T3 (pl) 2007-08-15 2011-04-29 Circassia Ltd Peptydy do odczulania na alergeny
WO2009079712A1 (en) 2007-12-24 2009-07-02 The University Of Queensland Coating method
EP2247527A4 (de) 2008-02-07 2014-10-29 Univ Queensland Patch-herstellung
WO2009140735A1 (en) 2008-05-23 2009-11-26 The University Of Queensland Analyte detection by microneedle patch with analyte selective reagents.
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
US8734697B2 (en) 2008-12-22 2014-05-27 The University Of Queensland Patch production
WO2012006677A1 (en) 2010-07-14 2012-01-19 The University Of Queensland Patch applying apparatus
WO2012058715A1 (en) 2010-11-01 2012-05-10 University Of Technology, Sydney Immune-modulating agents and uses therefor
US8609621B2 (en) 2010-11-15 2013-12-17 E I Du Pont De Nemours And Company Acid-cleavable linkers exhibiting altered rates of acid hydrolysis
AU2012323782B2 (en) 2011-10-12 2017-04-06 Vaxxas Pty Limited Delivery device
US11147954B2 (en) 2015-02-02 2021-10-19 Vaxxas Pty Limited Microprojection array applicator and method
WO2017045031A1 (en) 2015-09-18 2017-03-23 Vaxxas Pty Limited Microprojection arrays with microprojections having large surface area profiles
EP4306803A3 (de) 2017-03-31 2024-04-10 Vaxxas Pty Limited Vorrichtung und verfahren zur beschichtung von oberflächen
EP3639010A4 (de) 2017-06-13 2021-03-17 Vaxxas Pty Limited Qualitätskontrolle von substratbeschichtungen
WO2019023757A1 (en) 2017-08-04 2019-02-07 Vaxxas Pty Limited COMPACT MECHANICAL HIGH ENERGY STORAGE ACTUATOR WITH LOW TRIGGER STRENGTH FOR ADMINISTRATION OF MICROPROJECTION NETWORK (PRM) PATCHES

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4163778A (en) * 1978-05-04 1979-08-07 The Foundation for the Study of Asthma and Related Diseases Asthma immunotherapy

Also Published As

Publication number Publication date
AU6733090A (en) 1991-05-31
NO921697L (no) 1992-07-03
WO1991006571A1 (en) 1991-05-16
DE69033949T2 (de) 2002-11-14
EP0500785B1 (de) 2002-04-17
DK0500785T3 (da) 2002-08-19
NO921697D0 (no) 1992-04-30
FI921979A0 (fi) 1992-04-30
FI921979A (fi) 1992-04-30
AU650249B2 (en) 1994-06-16
JPH05502445A (ja) 1993-04-28
ATE216401T1 (de) 2002-05-15
ES2174822T3 (es) 2002-11-16
CA2073045C (en) 2007-05-22
CA2073045A1 (en) 1991-05-04
EP0500785A1 (de) 1992-09-02
JP3251012B2 (ja) 2002-01-28

Similar Documents

Publication Publication Date Title
DE69033949T2 (de) Aus hausstaub isoliertes t-zellreaktives katzenprotein, und dessen verwendungen
Mundy et al. Big and little forms of osteoclast activating factor
IE891542L (en) Peptides having t cell helper activity
HK1022918A1 (en) Modified tnfalpha molecules, dna encoding such modified tnfalpha molecules and vaccines comprising such modified tnfalpha molecules and dna
GR3030811T3 (en) Proteins produced by human lymphocytes, dna sequence coding these proteins, and pharmaceutical and biological uses thereof
DK0573551T3 (da) Serinrige peptidlinkere
ATE87655T1 (de) Markierer der t-zelle aktivierung.
ATE449965T1 (de) Diagnostisches und therapeutisches epitop
ATE198754T1 (de) Antikörper gegen saugetier-interleukin-4 und peptide verwendbar als antigenen für deren herstellung
FI941757A (fi) Dermatofagoideista (talopölypunkki) peräisin olevien pääallergeenien T-soluepitoopit
SE9002589D0 (sv) Neutrofil-aktiverande peptid-2
ZA891861B (en) Monoclonal antibodies
SE8902148D0 (sv) Syntetiska peptid antigen foer detektion av htlv-1 infektion
JO1671B1 (en) New ways to diagnose tuberculosis
SE9002212D0 (sv) Igg binding protein
DeOgny et al. Solid-phase synthesis of biologically active lipopeptides as analogs for spirochetal lipoproteins
ATE143813T1 (de) Reagenz für bilderzeugung und therapie von tumoren
DE69724761D1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
EP0723016A3 (de) Leukocyten-aktivierender Faktor
Onozaki et al. Production of an antibody against guinea pig MIF: II. Analysis of the antibody-reacting material using radiolabeled lymphokines
DE69332583T2 (de) Maspin- ein neues serpin mit tumor unterdrückender aktivität
DE69900283T2 (de) Reninaktive Substanz enthaltend humanes Prorenin und Antikörper gegen das Prorenin Profragment
EP0915099A1 (de) Antiparallele und hydrophob-komplementäre Oligopeptide, diese enthaltende Matrizen und deren Verwendung zur Reinigung sowie zum Nachweis von IFN-alpha Subtypen
SE9101586D0 (sv) Modified thioredoxin and its use

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: HESKA CORP.(N.D.GES,D.STAATES DELAWARE), LOVELAND,

8327 Change in the person/name/address of the patent owner

Owner name: MERCK PATENT GMBH, 64293 DARMSTADT, DE